Member Info for Cloudy390

https://www.sec.gov/Archives/edgar/data/0001850767/000119312521177289/d172836d20fr12ga.htm#tx172836_6
Page 30/31
States the process of commercialisation
Which seems pretty straightforward.

There is along way to progress Accustem at all.
It’s already been tried and test in about 3500 people, Royal Marsden must have had the actual product to test, CE marking is not complicated and after that FDA approval ,after was it , CIMA approval , should be forth coming GC said something about it and I read it in SEC link someone else posted earlier.

All stated is /has happened!
End of this year I think was mentioned to be up and running, office in Milan, product ready to go,
Share trading history on OTC, Bingo Nasdaq listing at $10 with an IPO raising $10\20 million ,job done. Wouldn’t that be nice!!

As they have stated that Sharetiks, I pressume that’s what they have done. As we at Accustem are no longer a ‘ listed regulated company’ they don’t have to tell us anything, and as getting a CE mark is only filling in forms a proving it conforms to relevant regs I can’t see why not!.
FDA approval will come after CE mark, it’s not a drug, no one is going to die from it , it’s just better diagnostics.

Paid for in shares!! We lose he gets nothing, come on open your eyes this will bite you in the ass if your not open minded, it’s gonna work, mark my words.

Seems trading has ?
Wonder if it’s because people realise now all trials were proper phase2 and we are well along the phase 2 road.
Big Bang coming , fingers crossed.

Everything seems to take to long!!
Expediate this ,
Accelerate that,
Nothing seems to happen!
What’s going on!!!!

We’re off , and there she goes , accelerating to infinity and beyond!!

What people don’t seem to realise is foralumab is and was a phase 2 asset when Tils bought it.
Novimmune took it to phase 2 with Crohns but IV injections caused problems, Bristol Meyers Squibb had the licence but we bought it for a “song”. We reformulated and re thought the way to get it in the body in a lot smaller doses and now it’s safe ,nontoxic , and efficacious. Boom Boom!!

This Accustem lark has got the whole system confused, I think it’s gonna blow a 50amp fuse.
Tils however could not be simpler it’s not nuclear bomb science. She’s gonna blow captain!!!!

not got mine. Don’t know where they are , but I have a suspicion all will be revealed soon.

One would have thought so Shakineven, but every thing seems to take ages to get done!! UK-CTAP
What are they doing!! Brazil COVID trial end October!!!crazy

Investor call only with Dave dodah at Redchip, all seems a bit pointless Redchip as a company supposed to be promoting Tils , no ones listening, we are tied into them for a year I presume so getting our own PR investor relations person on board will have to wait till Redchip are gone!

Agree ROCKZ , the science backs it up, scientists back it up and they are not yo-yo s, it seems ridiculous why we are not valued fairly more so now than the past but saying that Milciclib is well in phase 2 and better than the standard of care available now we are told by results and scientists, and we are not on Mickey Mouse markets we are on NASDAQ and LSE, it’s just ludicrous. Something has got to give!!!
And all our products so far have proved to safe and nontoxic.

Official Title: A Phase 2 Proof-of-concept Study to Evaluate the Safety, Tolerability, and Efficacy of Intranasal Foralumab in Hospitalized Subjects With Severe COVID-19 and Pulmonary Inflammation.

This is it proof of concept, positive results, billion dollar company , Chairman and CEO said so.
No argument now , official clinical trial, phase 2, independent world renowned people managing it, no doubt this is it!!
MS trial goes well, a phase 2 trial as well, positive results , bingo, 2billion dollar company. It’s not a time to me out, we are moving forward.

I reckon Tils will float around £3 mark when trial starts and escalate as MS and Alzheimer’s news comes in let alone milciclib in Asian market and news of IL6 mab which was accelerated comes in.
I would not want to be out of this at this level. But hay takes allsorts.

As someone said GC has turned down offers, May be said offerers have sour grapes .

We are in phase 2 for everything foralumab Tils wants to try, as long as safety trials are undertaken, which they have.IMO
MS trial is phase 2 , we are well in phase2 now so as that graph showed we are worth well over $500mill so what’s happening????

To be fair ROCKZ why would they do that, all the info is out there so it seems a bit pointless, Why should they care about shareholders who haven’t a clue what there invested in , no offence. They got loads a money ,enough to see them through this, good or bad I see this as make or break, yes it will be a few months maybe a year but Tils is still here.

Exactly Bluebelly, when Tils got the license for foralumab is was Phase2 asset from novimmune.
I think because it was IV administered it had some unwarranted side effects, no one died, but I think they gave up, and a while ago I was researching mabs and foralumab was in list but use was unknown, I think tils has found a use now as different methods of administration and a lot low dose seems to be sweet. Rock on !!!